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ORIGINAL PAPER
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Abstract
In addition to motor neurone degeneration, up to 50% of amyotrophic lateral sclerosis (ALS) patients present with cognitive 
decline. Understanding the neurobiological changes underlying these cognitive deficits is critical, as cognitively impaired 
patients exhibit a shorter survival time from symptom onset. Given the pathogenic role of synapse loss in other neurodegen-
erative diseases in which cognitive decline is apparent, such as Alzheimer’s disease, we aimed to assess synaptic integrity 
in the ALS brain. Here, we have applied a unique combination of high-resolution imaging of post-mortem tissue with neu-
ropathology, genetic screening and cognitive profiling of ALS cases. Analyses of more than 1 million synapses using two 
complimentary high-resolution techniques (electron microscopy and array tomography) revealed a loss of synapses from 
the prefrontal cortex of ALS patients. Importantly, synapse loss was significantly greater in cognitively impaired cases and 
was not due to cortical atrophy, nor associated with dementia-associated neuropathology. Interestingly, we found a trend 
between pTDP-43 pathology and synapse loss in the frontal cortex and discovered pTDP-43 puncta at a subset of synapses 
in the ALS brains. From these data, we postulate that synapse loss in the prefrontal cortex represents an underlying neuro-
biological substrate of cognitive decline in ALS.
Introduction
Amyotrophic lateral sclerosis (ALS) is the most com-
mon form of motor neurone disease (MND), resulting in 
progressive upper and lower motor neurone dysfunction 
and loss. This leads to progressively severe muscle wast-
ing and most patients succumb due to respiratory failure, 
with a mean survival time of 3 years post diagnosis [57]. 
Due to the striking, and in many cases rapid, deteriora-
tion of motor function, ALS was historically considered a 
homogenous disease of the motor system. However, both 
clinical and post-mortem studies increasingly describe 
ALS as a heterogeneous disorder, with around 50% of 
patients exhibiting neuropsychological deficits due pre-
sumably to breakdown of non-motor areas of the brain 
[49]. ALS is thought to lie on a disease spectrum with 
frontotemporal dementia (FTD). These seemingly dispa-
rate disorders share both genetic and pathological features 
[30] with considerable clinical overlap. An estimated 15% 
of FTD patients present with motor decline meeting the 
criteria for ALS diagnosis and 15% of ALS cases show 
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severe cognitive and or behavioral decline, meeting the 
FTD diagnostic criteria [24, 30, 49]. However, a further 
30–40% of ALS patients show milder, more specific cog-
nitive and/or behavior changes (ALS cognitive impair-
ment—ALSci/ALS behavioral impairment ALSbi [49]) 
that does not meet FTD diagnostic criteria but can still 
affect daily life [20]. Changes include executive dysfunc-
tion, decreased verbal fluency, language impairment and 
social cognition deficits, which are thought to be medi-
ated by regions of the frontal cortex and are similar to 
mild FTD-associated impairments [20]. Behavior change 
is predominantly one of the apathies, while other features 
of FTD are also seen, including disinhibition and loss of 
sympathy/empathy [20]. Functional and structural imaging 
studies support the presence of frontal deficits [11, 34, 47, 
56], and specifically relate dysfunction of the dorsolateral 
prefrontal cortex [including Brodmann Area 9 (BA9)] to 
the cognitive profile in ALS [1, 2]. It is vitally important 
that we understand the underlying neuropathology driving 
these cognitive deficits, as cognitively impaired patients 
not only endure the personal burden of both motor and 
cognitive dysfunction, but also exhibit a shorter survival 
time from symptom onset [15, 58].
Synapse degeneration is a common feature in a large 
number of neurodegenerative diseases and often plays a 
role in pathogenesis, rather than simply occurring as a 
secondary effect of neuron loss [22]. For example, syn-
apse loss remains the strongest neurobiological correlate 
of cognitive decline in Alzheimer’s disease (AD [54]). In 
AD, synaptic accumulation of key pathological forms of 
tau and beta-amyloid are thought to drive synaptic break-
down [48]. Likewise, studies in ALS mouse models have 
suggested that synapse defects in motor regions of the cor-
tex are an early/pre-symptomatic feature of the disease 
[18, 43]. However, to date, few studies have attempted to 
assess the contribution of synaptic change to pathology 
of non-motor cortical regions in the brain of human ALS 
patients and none using direct measurement in patients 
with defined ALS with cognitive impairment.
By combining the high-resolution imaging techniques 
of array tomography and transmission electron micros-
copy (TEM), we have examined synapses in the frontal 
cortex and motor cortex of cognitively unimpaired and 
cognitively impaired ALS (ALSci) patients, to define the 
relationship between synaptic breakdown and cognitive 
impairment. Cognitive profiling was performed using 
the Edinburgh Cognitive and Behavioural ALS Screen 
(ECAS) [3], a short multi-domain assessment designed for 
people with physical disability which has been validated 
against extensive neuropsychology [38]. Other post-mor-
tem measurements such as cortical thickness, pathological 
burden and gliosis were recorded to ensure a comprehen-
sive profiling of each case.
Materials and methods
Participant characteristics
All patients had clinical and electrophysiological evidence 
of combined upper and lower motor neurone involvement 
and fulfilled the revised El Escorial criteria for a diagnosis 
of ALS [10]. Patients were recruited through the Scot-
tish Motor Neurone Disease Register and data collected 
in the CARE-MND database (Clinical Audit Research 
and Evaluation). Ethical approval for this register was 
obtained from Scotland A Research Ethics Committee 10/
MRE00/78 and 15/SS/0216. All clinical data were subse-
quently extracted from the CARE-MND database. Clinical 
details can be seen in Table 1. There was no documented 
evidence of dementia in the CARE-MND database.
Patients gave pre-mortem consent for brain and spinal 
cord donation. All tissue retrievals were in line with the 
Human Tissue (Scotland) Act, and all procedures have 
been approved by a national ethics committee. Use of 
human tissue for post-mortem studies has been reviewed 
and approved by the Sudden Death Brain Bank ethics com-
mittee and the ACCORD medical research ethics com-
mittee, AMREC (ACCORD is the Academic and Clinical 
Central Office for Research and Development, a joint office 
of the University of Edinburgh and NHS Lothian). Fur-
ther, some brains from human subjects with no cognitive 
deficits were obtained through the Massachusetts Alzhei-
mer’s Disease Research Centre and Massachusetts General 
Hospital Neuropathology department. All donor tissue was 
obtained in accord with local and National Institutional 
Review Board regulations. Details of all donors used in 
this study can be found in Supplementary Table 1, with 
means for each group found below in Table 1.
At post-mortem, the brain was removed as detailed in 
[46] and cut into coronal slices. Regions of interest were 
then dissected from each coronal slice. Each region of 
interest from one hemisphere was then processed for par-
affin embedding. Samples from the other hemisphere were 
dissected into smaller segments then processed for array 
tomography or transmission electron microscopy (see 
below for details).
Cognitive profiling
The ECAS is a brief multi-domain assessment which is 
specifically designed for ALS. It includes the assessment 
of domains which are typically affected in ALS (Fluency, 
Executive and Language functions) and which together 
produce an ALS-Specific Score (max 100). It also includes 
the assessment of domains which are more typically 
215Acta Neuropathologica (2018) 135:213–226 
1 3
Ta
bl
e 
1 
 Su
m
m
ar
y d
em
og
ra
ph
ics
 of
 al
l d
on
or
s
PM
 po
st-
m
or
tem
, E
CA
S E
di
nb
ur
gh
 C
og
ni
tiv
e a
nd
 B
eh
av
io
ra
l A
LS
 S
cr
ee
n, 
EM
 el
ec
tro
n m
icr
os
co
py
, A
LS
ci
 A
LS
 w
ith
 co
gn
iti
ve
 im
pa
irm
en
t
Nu
m
be
r
M
ale
/fe
m
ale
Ag
e a
t d
iag
no
sis
(m
ed
ian
 +
 ra
ng
e)
Ag
e a
t P
M
(m
ed
ian
 +
 ra
ng
e)
Si
te 
of
 on
se
t
Ri
lu
zo
le 
(y
es
/n
o)
Di
se
as
e d
ur
ati
on
(m
on
th
s)
Ti
m
e b
etw
ee
n 
EC
AS
 an
d d
ea
th
(m
on
th
s)
EC
AS
 to
tal
(m
ea
n ±
 S
D)
AL
S-
sp
ec
ifi
c E
CA
S
(m
ea
n ±
 S
D)
Co
ho
rt 
1-
EM
Co
nt
ro
l
5
4/
1
61
 (5
3–
77
)
AL
S
20
9/
11
63
 (4
0–
89
)
Co
ho
rt 
2a
-a
rr
ay
 to
m
og
ra
ph
y
Co
nt
ro
l
14
11
/3
79
 (6
2–
95
)
AL
S
29
18
/1
1
60
 (3
2–
75
)
64
 (4
0–
89
)
20
 L
im
b, 
7 b
ul
ba
r
17
/9
44
 (1
7–
21
6)
Co
ho
rt 
2b
 (s
ub
se
t o
f c
oh
or
t 2
)-c
og
ni
tiv
e p
ro
fil
in
g
Co
nt
ro
l
14
11
/3
79
 (6
2–
95
)
AL
S
16
9/
7
60
 (3
2–
71
)
64
 (4
0–
83
)
11
 L
im
b, 
5 b
ul
ba
r
4/
6
39
 (2
4–
21
6)
17
 (4
–4
2)
11
6 ±
 4.
9
86
 ±
 3.
6
AL
Sc
i
7
4/
3
61
 (3
8–
72
)
68
 (4
3–
75
)
4 L
im
b, 
2 b
ul
ba
r
4/
3
49
 (3
4–
64
)
14
 (3
–6
1)
98
 ±
 5.
9
72
 ±
 7.
1
Co
ho
rt 
3-
CS
F
AL
S
9
6/
3
58
 (4
1–
69
)
3 L
im
b, 
1 b
ul
ba
r,
5 m
ixe
d (
bu
lb
ar
 an
d l
im
b)
28
 (1
2–
84
)
11
2.6
 ±
 5.
5
AL
Sc
i
6
4/
2
72
 (6
5–
80
)
5 L
im
b, 
1 b
ul
ba
r
15
 (1
–3
6)
62
.3 
± 
16
.6
216 Acta Neuropathologica (2018) 135:213–226
1 3
affected in other disorders such as Alzheimer’s disease 
(Memory, Visuospatial Functions) and which make up 
the ALS non-specific score (max 36). Together, the com-
bined ALS-specific and ALS non-specific scores produce 
an ECAS total Score (max 136). The assessment has been 
validated against extensive neuropsychology and provides 
high sensitivity and specificity using published cut-offs 
with patients classified as ALSci if ALS-specific and/or 
ECAS total Scores are below threshold [38]. It also shows 
good convergent validity with other screens not designed 
for ALS [31, 41].
Genetics
A subset of our patient participants actively consented to 
donate blood and saliva to the Scottish Regenerative Neurol-
ogy Tissue Bank for genetic analysis. Use of patient sam-
ples for genetic profiling has been approved by the Chief 
Scientist Office Scotland; MREC/98/0/56 1989–2010, 
10/MRE00/77 2011–2013, 13/ES/0126 2013–2015, 15/
ES/0094 2015-present. C9orf72 genotyping was performed 
as described in [12] and most cases were genetically ana-
lyzed as described in [5]. Some cases were analyzed by next 
generation sequencing to screen for variants in the coding 
regions of SOD1, TARDBP, FUS, VCP, UBQLN2, SQSTM1, 
CHMP2B and VAPB. Library construction was carried out 
using the Ion Ampliseq library kit v2.0 (Life Technolo-
gies). Emulsion PCR and enrichment was performed using 
the Ion OneTouch2 instrument (200p template kit) and Ion 
ES module. Sequencing was carried out on an Ion Torrent 
Personal Genome Machine (Life Technologies) using the Ion 
PGM sequencing 200 kit v2 and an Ion 316 chip. All stages 
followed the manufacturer’s protocols. NextGENe soft-
ware (Softgenetics) was used with hg19 (GRCh37) human 
genome as reference to identify variants.
Neuropathology
Fresh post-mortem tissue blocks were fixed in 10% formalin 
for a minimum of 24 h. Tissue was dehydrated in an ascend-
ing alcohol series (70–100%), followed by three xylene 
washes, all for 4 h each. Next, three paraffin waxing stages 
(5 h each) were performed to ensure full penetration of the 
embedding wax and the blocks were cooled. Tissue sections 
were cut on a Leica microtome at 4 μm and collected on 
glass slides. All sections were dried at 40 °C for at least 24 h 
before staining. Immunohistochemistry was performed using 
standard protocols, enhanced using the Novolink Polymer 
detection system and visualized using DAB as chromogen. 
See Table 2 for antibody information. Slides were finally 
counterstained with hematoxylin for 30 s to stain cell nuclei. 
For each staining run, positive and negative control tissue 
for each pathological marker were used to ensure specificity 
and success of each experiment. All staining was performed 
by experimenters blind to clinical diagnosis.
For pTDP-43 and pTau analysis, cases were described 
as being positive or negative depending on the presence of 
clearly stained protein aggregates.
Burden quantification
All sections stained for β-amyloid, CD68 or GFAP was 
assessed for plaque, microglia and astrocytic burden, respec-
tively, using Stereo Investigator. Cortical gray matter was 
outlined in each section and immune-positive objects identi-
fied using an automated color-based thresholding algorithm. 
The area of immuno-positive cortex was expressed as a per-
centage of total cortex in each brain region. All imaging and 
analysis were performed by experimenters blind to clinical 
diagnosis.
Table 2  Primary antibody information
Histopathology
Antibody Company Code Dilution Pre-treatment
Beta amyloid (BA4) Dako M087201-2 1:100 98% Formic acid 5 min
pTDP-43 2B Scientific CAC-TIP-PTD-MO1 1:4000 Pressure cooker/citric acid
pTau (AT8) Thermo MN1020 1:2500 None
GFAP Dako Z0334 1:800 None
CD68 Dako M0876 1:100 Pressure cooker/citric acid
Array tomography
Antibody Company Code Dilution Secondary antibody
Synaptophysin Abcam Ab8049 1:50 Donkey α Mouse—AF594 or AF488
PSD95 Synaptic Systems 124,014 1:50 Donkey α Guinea Pig—AF647
pTDP-43 Proteintech 22309-1-AP 1:50 Donkey α Rabbit—AF594 or AF488
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Cortical thickness
Gray matter thickness was calculated at ten randomly 
selected points throughout each section. Thickness was 
measured from the pial surface to the border of grey/white 
matter, below cortical layer 6. All ten measurements were 
averaged to give a cortical thickness for each brain region. 
All imaging and analysis weres performed by experimenters 
blind to clinical diagnosis.
Neuron counts
Paraffin-embedded sections from the frontal cortex of 10 
ALS cases were used to assess neuronal density as previ-
ously described [21]. The five ALS cases with the highest 
and the five with the lowest synapse density as measured by 
array tomography were analyzed. All imaging and analysis 
were performed by experimenters blind to clinical diagnosis.
Neurofilament light‑chain CSF ELISA
Fifteen patients provided CSF for this study. Patients were 
seen at the Department of Neurology in Ulm. The study, 
whose overall aim was to find biomarkers for neurologi-
cal diseases, was approved by the local ethics committee 
in Ulm according to institutional guidelines and patients 
provided written informed consent to participate (approval 
number 20/10). A summary of patient group characteristics 
is given in Supplementary Table 1. The physical function 
of ALS patients’ status was classified with the revised ALS 
functional rating scale (ALSFRS-R) with a maximum of 48 
points, where lower values represent a more severe disease 
stage.
CSF was obtained by lumbar puncture, centrifuged, ali-
quoted and stored within 2 h at − 80 °C until analysis. Neu-
rofilament light-chain levels in the CSF were examined using 
a commercial 96-well ELISA kit from UmanDiagnostics 
(Umea, Sweden). CSF samples were diluted 1:20 in sample 
diluent before analysis and the ELISA was run according to 
the manufacturer’s instructions, with all CSF samples and 
kit standards run in duplicate.
Electron microscopy
Fresh post-mortem samples, stored in 0.1  M  PB were 
trimmed into small cortical blocks and fixed in 4% para-
formaldehyde and 2.5% glutaraldehyde in 0.1 M PB for 3 h. 
Fixed blocks were washed twice in 0.1 M PB before being 
cut at 70 μm with a vibratome. Sections were then treated 
with osmium tetroxide (1% in 0.1 M PB) for 30 min (pro-
tected from light) and dehydrated in an ascending series of 
ethanol and propylene oxide, before embedding in Durcupan 
resin. During dehydration, the sections were treated with 
uranyl acetate (1% in 70% ethanol) for 40 min in the dark. 
Durcupan resin was polymerized for 48 h at 56 °C. Small 
regions of interest were cut from the Durcupan-embedded 
sections and glued onto Durcupan blocks, before cutting into 
70 nm ribbons using an ultracut microtome (Leica) with a 
Jumbo Histo Diamond Knife (Diatome, Hatfield, PA). Rib-
bons were collected on grids and stained with lead citrate 
before imaging on a Philips CM12 transmission electron 
microscope equipped with a Gatan digital camera. Qualita-
tive and quantitative synapse analyses were performed by an 
investigator who was blinded to the disease status of each 
sample. Individual synaptic profiles were identified based on 
the presence of clear pre- and post-synaptic terminals, con-
taining synaptic vesicles and post-synaptic density, respec-
tively. Degenerating synapses were classified as those with 
an electron-dense cytoplasm, as previously described [19, 
26].
Array tomography
Brain samples were prepared for array tomography as out-
lined previously [26]. Briefly, fresh post-mortem tissue was 
trimmed into small cortical blocks and fixed in 4% para-
formaldehyde and 2.5% sucrose in PBS for 2–3 h. Samples 
were then dehydrated through ascending ethanol washes 
and into LR White resin (Electron Microscopy Sciences) 
overnight. Blocks were placed individually into capsules 
containing LR White and polymerized overnight at 53 °C. 
Tissue blocks were cut into ribbons of 70 nm serial sections 
using an ultracut microtome (Leica) with a Histo Jumbo Dia-
mond Knife (Diatome, Hatfield, PA) and collected on gel-
atin-coated glass coverslips. For synaptic density analysis, 
ribbons were immunostained as described previously [21], 
with a primary antibody against synaptophysin overnight 
(see Table 2 for antibody details) and no primary negative 
control was included to rule out non-specific binding of the 
secondary antibodies. The following day, the staining was 
developed with a fluorescently labeled secondary antibody 
(1:50 dilution) and finally mounted onto slides with Immu-
mount mounting media. To obtain improved staining with 
the pTDP-43 antibody, array ribbons underwent epitope 
retrieval. Ribbons were pressure-cooked for 2 min in citrate 
buffer (pH 6), and then allowed to cool to room tempera-
ture. Ribbons were washed with TBS (2 × 5 mins) and then 
underwent the same staining protocol as described above. 
Three antibodies were used in combination (see Table 2 
for details), to analyze the presynapse (synaptophysin), 
postsynapse (PSD95) and pTDP43 co-localization. Once 
the ribbons had been stained and mounted, images were 
obtained at the same position on each section along the rib-
bon, using a Zeiss axio Imager Z2 epifluorescent microscope 
equipped CoolSnap digital camera and AxioImager software 
with array tomography macros (Carl Zeiss, Ltd, Cambridge 
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UK). First, a tile scan of the entire ribbon was obtained at 
10× magnification; then regions of interest were chosen on 
the tilescan and a position list generated. High-resolution 
images were obtained from the position list with a 63× 1.4 
NA Plan Apochromat objective. At least two image stacks 
were captured from at least two tissue blocks per region, per 
case. This meant at least four image stacks were captured per 
region for each case.
Stacks were aligned using the MultiStackReg ImageJ 
plugin [55]. Regions of interest (ROI) were automatically 
chosen in the neuropil of each aligned image stack using 
an in-house MATLAB cropping script and coded for blind 
analysis, before thresholding with an automated algorithm 
in ImageJ. To remove false background staining which was 
only found on single sections, we used the Watershed script 
[35] which also provides 3-dimensional (3D) object counts. 
These 3D objects (synaptic puncta) were used to generate 
synapse densities (synaptic puncta per  mm3) based on the 
ROI volume. All individual ROI synapse densities (between 
100 and 300 ROIs per region, per case) from each region, 
from each case were combined and a mean density value 
generated. All imaging and analysis were performed by 
experimenters blind to clinical diagnosis.
Statistics
GraphPad Prism 7.02 was used to test data for normality 
(D’Agostino and Pearson normality test). A mean or median 
for each subject was calculated for each measurement, fol-
lowing which parametric (t test or ANOVA) or non-paramet-
ric (Mann–Whitney or Kruskal–Wallis) tests were performed 
as required. Significance was reported when p < 0.05. Data 
are usually presented as mean ± standard deviation, unless 
otherwise stated.
Data sharing
Data used in this manuscript including custom image analy-
sis scripts for ImageJ will be freely shared on the Univer-
sity of Edinburgh Data Repository. Analysis macros can 
be found at the following link: http s://dx.doi.org/10.7488 /
ds/2268 . Original raw image files can be found at the fol-
lowing link: http ://dx.doi.org/10.7488 /ds/2269 .
Results
Transmission electron microscopy (TEM) analysis of the 
prefrontal cortex [Brodmann Area 9 (BA9); ~ 150 synapses 
per case] from 5 control and 20 ALS cases (Table 1; cohort 
1) revealed a significant decrease in synaptic density in the 
ALS cohort (Fig. 1a–c). In addition, there was a significant 
increase in the number of electron-dense, degenerating 
pre-synaptic terminals in ALS cases compared to controls 
(Fig. 1b, d) [19].
To expand our synaptic analyses, we next examined a 
largely independent cohort (Table 1; cohort 2a) of subjects 
using higher-throughput array tomography. Analysis of over 
1 million synapses (~ 36,000 synapses per case) from 14 
controls and 29 ALS brains using array tomography con-
firmed our initial TEM findings revealing synapse loss in 
BA9 of ALS patients (2-tailed unpaired t test; p = 0.013; 
Fig. 1e–g). Post-mortem interval (PMI) did not influence 
synapse density (Pearson r = − 0.21, p = 0.17). Importantly, 
the loss of synaptic density was not accompanied by any 
detectable gross atrophy of BA9 (2-tailed unpaired t test; 
p = 0.68; Fig. 1h). Furthermore, stereological estimates of 
neuron density counts from 5 cases with the highest and 
lowest synapse densities were not significantly different 
(Low: n = 5, 23,370 ± 2756 neurons/mm3; High: n = 5, 
28068  ±  2094  neurons/mm3. Unpaired 2-tailed t test; 
p = 0.22), suggesting that synapse loss was occurring in the 
absence of concomitant, overt neuronal loss.
We then performed some exploratory analyses to assess 
the influence of numerous genetic and pathological factors 
that may associate with increased synapse loss. Genetic 
screening revealed that 6 ALS cases had a hexanucleotide 
repeat expansion in C9orf72, 3 cases had SOD1 variations 
and 2 had NEK1 variations (Supplementary Table 1). How-
ever, we did not observe any significant association between 
lower synapse density in BA9 and distinct genetic mutations 
in ALS with this sample size (Fig. 1g; Supp. Fig. 1).
Pathological changes in disease-associated proteins 
are strongly implicated in driving synapse degeneration 
in dementias [48]. Thus, we next assessed the presence of 
disease-associated pathological aggregates in formalin-fixed 
paraffin-embedded (FFPE) sections from BA9 and their 
association with synapse loss in array tissue from the same 
case. We found no association between the presence of beta-
amyloid or pTau pathology in BA9 and synapse loss (Supp. 
Fig. 2). We also found no association between the presence 
of pTDP-43 aggregates in BA9 and synapse loss (Supp. 
Fig. 3). However, it is known that ALS patients with SOD1 
mutations do not express pTDP-43 pathology [32]. When 
we remove our three SOD1 + ve cases from the analysis, 
we find a significantly lower synapse density in ALS cases 
with pTDP-43 pathology (Supp. Fig. 3). Due to this potential 
association and to the literature from Alzheimer’s disease in 
particular, indicating that pathological protein accumulation 
at synapses can drive synapse degeneration [48], we used 
array tomography to assess the presence of pTDP-43 at the 
synapse. We observed pTDP-43 pathology in all of the 9 
ALS cases screened, often exhibiting as large cytoplasmic 
aggregates or neuritic threads (Fig. 1i). Interestingly, we also 
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noticed small pTDP-43 puncta in the neuropil of our 9 cases, 
which in a subset of synapses co-localized with synaptic 
markers (Fig. 1i, j).
Twenty-three patients from whom we collected tissue 
for array tomography had previously been cognitively 
profiled using the Edinburgh Cognitive and Behavioural 
ALS Screen (ECAS). These individuals (Table 1; cohort 
2b) were classified as unimpaired (ALS) or ALS with 
cognitive impairment (ALSci) according to established 
threshold scores for ECAS Total or ALS-specific ECAS 
results [3]. The scores revealed 16 unimpaired cases and 7 
impaired cases [70% unimpaired, 30% impaired (Fig. 2a)]. 
Comparing ECAS data with synaptic data, we found a sig-
nificant difference between our three groups in synaptic 
Fig. 1  Synapse loss in ALS frontal cortex. Representative elec-
tron micrographs showing two excitatory synapses in the frontal 
cortex of a healthy control (a) and an ALS case (b). Edges of the 
post-synaptic density (PSD) are marked by red arrowheads and pre-
synaptic terminals by black asterisks. The white asterisk in b high-
lights an electron dense, degenerating presynaptic terminal. Scale 
bars 100  nm. Decrease in synaptic density in the frontal cortex 
[(c) 2-tailed unpaired t test; p  =  0.016], and increased numbers of 
degenerating synapses [(d) 2-tailed Mann–Whitney test; p = 0.014] 
in ALS patients (n  =  20) compared to controls (n  =  5), measured 
using TEM. Each data point represents the mean total synapse (c) 
or degenerating synapse (d) count per 100  µm2 for each individual. 
Three-dimensional reconstructions of fifteen 70  nm array tomog-
raphy sections from a control frontal cortex (e) and an ALS frontal 
cortex (f), stained for synaptophysin (green) and DAPI (white). Scale 
bar is 10 µm. g Decrease in synaptic puncta (2-tailed unpaired t test; 
p  =  0.017) in ALS patients compared to controls, measured using 
array tomography. Each data point represents the mean synapse count 
per  mm3 of frontal cortex, for each individual (control n = 14; ALS 
n = 29). Blue icons = C9orf72 expansions, Red icons = SOD1 vari-
ant and Green icons = NEK1 variant. h Cortical thickness compari-
sons between control (n = 7) and ALS (n = 34) revealed no differ-
ence (2-tailed unpaired t test; p = 0.76). Each data point represents 
the mean of ten measurements per cortical block. All histogram bars 
plot the mean  ±  SD. i 3D reconstruction of 25 array tomography 
sections (each 70 nm thick), stained for synaptophysin (red), PSD95 
(blue), pTDP-43 (green) and DAPI (white). A large perinuclear 
pTDP-43 aggregate (white arrow), numerous pTDP-43 + ve neuritic 
threads (white arrowheads) and small pTDP-43 puncta (open arrows) 
are clearly visible. Scale bar 10 µm. By cropping the image in i, com-
pressing 3 consecutive sections and then splitting the channels, it is 
evident in panel (j) that pTDP-43 aggregates are found both in some 
pre (synaptophysin, red) and post (PSD95, blue) synaptic compart-
ments. Scale bar 1 µm
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density and that the cognitively impaired group had a 
significantly lower synapse density in BA9 than controls 
(Fig. 2b). We found no significant difference between the 
ALS unimpaired cohort and either controls or ALSci, 
most likely due to two cases with very low densities in the 
unimpaired group (Fig. 2b). When we plotted ECAS score 
versus synapse density, we found no significant correlation 
between these data (Pearson r = 0.31, p = 0.15), again due 
to the influence of the two unimpaired cases with low syn-
apse density mentioned above (Supp. Fig. 4). One potential 
confounding factor is the length of time between cognitive 
testing and post-mortem synapse analysis. However, we 
found no correlation between synapse density at post-mor-
tem and time since cognitive testing (Pearson r = 0.043, 
p = 0.85). Although there was no association between 
genetic status and synapse density or cognitive impair-
ment, it was interesting to note that 3 of our 4 genetically 
screened cognitively impaired cases were positive for 
C9orf72 repeat expansions (Fig. 2b), warranting further 
study of the effects of C9orf72 expansions, as more cases 
prepared for these techniques become available. Cortical 
thickness did not vary between the groups (ALS, ALSci, 
Controls) (Fig. 2c), suggesting that atrophy and overt neu-
ron loss were not driving cognitive decline. We found no 
association between age and ECAS score (Supp. Fig. 5) or 
cortical thickness and ECAS score (Supp. Fig. 5). Further-
more, the presence of beta-amyloid or pTDP-43 pathology 
in BA9 did not associate with lower ECAS score (Fig. 2d, 
f). Interestingly, although the presence of pTau pathology 
did not associate with a lower mean ECAS score (Fig. 2e), 
pTau + ve cases were predominantly ALSci (5 of the 7 
pTau + ve cases were ALSci), whereas pTau-ve cases 
were predominately unimpaired ALS cases (12 of the 14 
pTau-ve cases were unimpaired ALS; Fisher’s exact test: 
Fig. 2  Synapse loss in the ALS frontal cortex associates with cogni-
tive decline. a Graph showing all 23 cognitively profiled cases and 
their total ECAS scores (squares) and ALS-specific ECAS scores 
(circles). Solid black line represents the performance threshold for 
abnormality for total ECAS score (105) and the dashed line for ALS-
specific ECAS score (77). This reveals 7 cases fell below the total 
ECAS threshold, indicating cognitive impairment and 6 of those 
cases fell below the ALS-specific threshold (red shapes). b Histogram 
showing synapse density in the frontal cortex of control, ALS unim-
paired (ALS) and ALS impaired (ALSci) cases. One-Way ANOVA 
revealed a significant difference between the groups (F  =  6.6; 
p = 0.004) and the Tukey post hoc test revealed a significant differ-
ence between control and ALSci (p  <  0.01). Open shapes  =  cases 
not genotyped, Blue icons = C9orf72 expansions, Red icons = SOD1 
variant and Green icons  =  NEK1 variant. c Cortical thickness did 
not differ between any of the groups (One-Way ANOVA; F = 0.46, 
p = 0.64). The presence of amyloid (d), pTau (e) or pTDP-43 (f) had 
no effect on cognitive score (2-tailed unpaired t tests; p > 0.05). Red 
icons = ALSci. All histogram bars plot the mean ± SD
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p = 0.005). This suggests that pTau pathology may associ-
ate with cognitive impairment and warrants further study 
once more cases become available.
Eleven of the ECAS-screened cases also underwent the 
ECAS behavior interview, which was completed by an 
informant/carer in vivo. Six cases were unimpaired and five 
were classified as ALS with behavioral impairment (ALSbi), 
with changes including apathy, lack of empathy and behav-
ioral disinhibition. Analysis revealed no difference in BA9 
synapse densities between the three groups of controls, ALS 
and ALSbi (One-way ANOVA; F = 1.93; p = 0.17).
Together, these data suggest that synapse density is a 
robust indicator of ECAS score and cognitive performance 
in ALS.
To address whether synapse breakdown, in the absence 
of cortical atrophy, is a global feature of pathology in the 
ALS brain, or a specific event occurring in the prefrontal 
cortex, we employed an array tomography approach to ana-
lyze ~ 750,000 synapses from the primary motor cortex. 
Comparing synapse density in 7 controls versus 25 ALS 
patients, we discovered no difference in synapse density 
(Fig. 3a–c). Grouping the BA4 synapse values based on cog-
nitive status did not reveal any difference in synapse density 
between the groups (Fig. 3d). However, there was signifi-
cant cortical thinning of the motor cortex in ALS patients 
compared to controls (Fig. 3e). When the ALS group was 
divided into unimpaired ALS and ALSci, it was found that 
both groups exhibited significant cortical atrophy compared 
to controls (Fig. 3f). Furthermore, the assessment of neu-
rofilament light-chain in the cerebrospinal fluid (CSF) of 
another cohort of ALS and ALSci patients (Table 1; cohort 
3) revealed comparable levels (ALS = 7950 ± 2030 pg/
ml, ALSci = 11,068 ± 3073 pg/ml. 2-tailed unpaired t 
test; p = 0.39), suggesting the presence of similar neuronal 
breakdown across the brain in both groups (Supp. Fig. 6). 
When comparing synapse density in the frontal cortex to 
the motor cortex within the healthy control brains, we dis-
covered a lower density in the motor cortex (Supp. Fig. 7; 
2-tailed paired t test p = 0.036). This difference in regional 
synapse density was also observed in the larger group of 
cognitively unimpaired ALS cases (Supp. Fig. 7; 2-tailed 
paired t test p = 0.005), but was lost in the ALSci cases 
(Supp. Fig. 7; 2-tailed paired t test p = 0.75). This may sug-
gest that synapse densities in the frontal cortex of ALSci 
brains had dropped to levels similar to those found in the 
motor cortex. We found no association between beta-amy-
loid, pTau or pTDP-43 pathology in BA4 and synapse den-
sity (Fig. 3g–i). Further, we found no association between 
beta-amyloid (Fig. 3j), pTau (Fig. 3k) or pTDP-43 (Fig. 3l) 
pathology in the motor cortex and cognitive score.
Glial cells are thought to play a prominent role in ALS 
pathogenesis [40], so we analyzed GFAP and CD68 bur-
dens as a measure of astrocyte and microglial activity, 
respectively, in both BA9 and BA4. We found no correlation 
between GFAP burden and synapse density (Supp. Fig. 8) 
in BA9 (Pearson r = 0.127, p = 0.51) or in BA4 (Pearson 
r = 0.16, p = 0.44). There was also no correlation between 
CD68 burden and synapse density (Supp. Fig. 8) in BA9 
(Pearson r = − 0.012, p = 0.95) or BA4 (Pearson r = 0.036, 
p = 0.86). Furthermore, there was no difference in GFAP or 
CD68 burden in BA9 (Supp. Fig. 8) in ALS patients com-
pared to ALSci (2-tailed unpaired t tests. GFAP: p = 0.09; 
CD68: p = 0.59). This suggests that synapse loss in the 
ALSci patients is not associated with altered gliosis.
Taken together, these data suggest that synapse degenera-
tion, occurring specifically within frontal (and not motor) 
cortex of ALS patients with cognitive deficits, is one under-
lying neurobiological contributor to cognitive decline. Of all 
of the pathological changes measured, synapse degeneration 
in BA9 was the strongest predictor of cognitive impairment.
Discussion
We have optimized a combination of cognitive and genetic 
profiling with post-mortem tissue collection, neuropathology 
and high-resolution subcellular analyses. Our human tissue 
collection and processing protocol [26] robustly preserves 
synaptic structures for both electron microscopy and array 
tomography analysis. To the best of our knowledge, this is 
the only ALS cohort in the world that has been extensively 
characterized to this level of detail.
A few previous studies attempted to assess synaptic 
changes in human post-mortem tissue using less direct meas-
urements such as optical density of immunohistochemical 
staining or western blotting [25, 45], but failed to observe 
any difference between ALS patients and controls. How-
ever, one potential confound is that we do not know the 
cognitive status of the patients in these studies [25, 45] and 
taken together our study highlights the importance of using 
highly precise, high-resolution approaches (such as array 
tomography and TEM) when studying synaptic changes in 
post-mortem material. One very recent study has detected 
a loss of synaptic terminals in the putamen and caudate of 
ALS patients, using immunohistochemical approaches [44]. 
Patients with severe cognitive decline meeting the diagnosis 
of FTD or FTD-MND had significant synaptic loss, whereas 
the ALS group had a more variable phenotype. Unfortu-
nately, the ALS group was not stratified by cognitive status, 
so we cannot discern whether the synapse loss is related to 
cognitive decline in the ALS cases [44].
Synapse loss is the strongest correlate of cognitive 
decline in Alzheimer’s disease [54] and a recent meta-anal-
ysis highlighted presynaptic terminals as the major site of 
early pathogenesis in the disease [14]. Therefore, the loss of 
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synapses from the frontal cortex of ALS patients described 
here fits well with the features of other disorders where cog-
nitive decline is observed.
ALS mouse models, including the  hSOD1G93A and 
 FUSR521C models, have revealed pre-symptomatic spine 
loss in the motor cortex [18] and sensorimotor cortex [43], 
respectively. Intriguingly, in the  hSOD1G93A model, early 
pre-symptomatic loss of spines on pyramidal cells in the 
medial prefrontal cortex preceded changes in dendritic 
arborization [17]. The earliest onset of anatomical change 
occurred in the motor cortex, with such severe neuronal 
breakdown that cortical thinning was detected at pre-symp-
tomatic time-points [17]. Thinning of the medial prefrontal 
cortex was only detected in adult diseased mice, by which 
time spine loss and dendritic changes were significant [17]. 
This temporal pattern of cortical breakdown observed in 
mouse models fits with our observations in human post-
mortem tissue. We observed synapse loss in the prefrontal 
cortex without neuron loss, yet found significant cortical 
thinning in the ALS motor cortex. Furthermore, our CSF 
results suggest that similar levels of neuronal breakdown 
occurred across the brain of ALS and ALSci groups (Supp. 
Fig. 5). This is most likely due to the cortical thinning 
observed in the motor cortex and supports our finding that 
synapse loss in the frontal cortex of ALSci patients is not 
due to neuronal loss.
Two human post-mortem studies have found greater 
expression of TDP-43 aggregates in the frontal cortex of 
patients with cognitive decline, compared to cognitively 
unimpaired ALS patients [9, 13]. TDP-43 aggregates are 
often found in the brain of ALS patients, and a sequential 
staging of pathology progression through the central nerv-
ous system has been described [8]. It is believed that TDP-
43 pathology may progress through synaptically connected 
brain regions [6, 16], in a similar manner to other neurode-
generative diseases [7], thus placing synapses at a crucial 
point in ALS pathogenesis. Furthermore, in a human TDP-
43 (hTDP43) overexpressing mouse model, synaptophysin 
loss was noted in whole brain homogenates [33] suggest-
ing that altered TDP-43 function may drive synapse loss. 
Intriguingly, four studies have described what appears to be 
“synaptic” labeling of pTDP-43 in the neuropil of human 
post-mortem cortex from ALS and FTD patients [4, 37, 44, 
53]. A recent study described pTDP-43 puncta in very close 
proximity to synaptophysin puncta in human ALS brain 
[53], with the suggestion that small pTDP-43 aggregates 
may be accumulating in dendritic spines. However, another 
recent study suggests pTDP-43 puncta co-localize with syn-
aptophysin [44], thus suggesting these small aggregates are 
in fact presynaptic. In support of this, we also noted punctate 
labeling of pTDP-43 in the neuropil of some of our ALS 
cases and found pTDP-43 puncta in a number of synapses in 
a subset of ALS cases (Fig. 1i, j). Given that synaptic accu-
mulation of pathological proteins in Alzheimer’s disease and 
FTLD-tau animal models drives synapse loss [27–29, 51, 
52], it is possible that a similar build-up of pTDP-43 in the 
ALS synapse may initiate synapse breakdown. An alterna-
tive explanation is the phagocytosis of synaptic components 
by pathologically active glial cells, as recently described in 
Alzheimer’s disease [23]. In support of this, we recently 
observed that when TDP-43 is specifically knocked out in 
microglial cells, they adopt a hyper-phagocytic phenotype. 
The microglial cells actively phagocytozed synapses, result-
ing in a significantly lower synaptic density in the cortex 
of these transgenic mice compared to controls [39]. Fur-
thermore, in a human cohort of ALS patients, pTDP-43 
positive cases had significantly higher expression of the 
phagocytic microglial marker CD-68 [39]. Interestingly, in 
our current study, we found the same result in the frontal 
cortex of ALS patients. Those with pTDP-43 in the frontal 
cortex had a higher CD-68 burden than ALS cases with-
out pTDP-43 (pTDP-43-positive n = 14, pTDP-43-negative 
n = 20; 2-tailed unpaired t test; p = 0.028). However, CD68 
expression did not correlate with synaptic density (Pearson 
r = − 0.012; p = 0.95) and thus further work is required to 
understand the role of phagocytic microglia in synapse loss.
We found no direct association between the presence of 
the dementia-associated pathologies, beta-amyloid and pTau 
in the frontal cortex and lower ECAS score (Fig. 2). This 
is in agreement with recent studies showing no association 
between Alzheimer’s pathology and cognition in ALS [9, 
42]. However, it is interesting to note that 5 out of the 7 
ALSci cases were positive for pTau and 5 of the 7 pTau + ve 
cases were ALSci. This finding aligns with the proposed 
model that certain forms of pTau in the frontal cortex may 
associate with cognitive decline in ALS [50, 59, 60] and 
warrants further study once more cases become available to 
Fig. 3  Synapse density in the ALS motor cortex does not associate 
with cognitive decline. Three-dimensional reconstruction of twenty-
four 70 nm array tomography sections from a control motor cortex (a) 
and an ALS motor cortex (b), stained for synaptophysin (green) and 
DAPI (white). Scale bar is 10 µm. c Histogram showing no change 
in synaptic puncta within the motor cortex (2-tailed unpaired t test; 
p = 0.73) between control and ALS. Each data point represents the 
mean synapse count per  mm3 of motor cortex, for each individual 
(control n = 7; ALS n = 25). d When split by cognitive status, there 
is no difference in synapse density within the motor cortex (One-Way 
ANOVA; F  =  0.06, p  =  0.94). e Histogram showing a significant 
decrease in the thickness of ALS motor cortex compared to controls 
(2-tailed unpaired t test; p = 0.0002). f Both ALS and ALSci motor 
cortices are significantly thinner than control (One-Way ANOVA; 
F = 9.98, p = 0.0006; Tukey post hoc test; p < 0.05 and p < 0.01, 
respectively). The presence of beta-amyloid (g), pTau (h) and pTDP-
43 (i) in the motor cortex, had no effect on synapse density (2-tailed 
unpaired t tests; p > 0.05). The presence of beta-amyloid (j), pTau (k) 
and pTDP-43 (l) in the motor cortex, had no effect on cognitive score 
(2-tailed unpaired t tests; p > 0.05). Red icons = ALSci. All histo-
gram bars plot the mean ± SD
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us. One of the limitations of this study is the small number 
of cognitively impaired patients who have donated brain 
tissue for these synaptic analyses. As more people donate 
tissue, we may be able to further dissect the contributions 
of pathological protein accumulation within synapses and 
genetic contributors to synaptic loss and cognitive decline. 
Another potential confound in the study is that the control 
group prepared for array tomography imaging was sig-
nificantly older than the ALS group (Table 1). However, 
since subtle age-related changes in synapse loss have been 
reported [36], we predict that this age discrepancy would 
make the detection of synapse loss in ALS more difficult 
and thus are confident that this age difference did not lessen 
the main finding of synapse loss in frontal cortex of ALS 
cases, which is worse with cognitive impairment. In support 
of this idea, we did not detect any correlation between age 
and synapse density in our data (Pearson r = 0.23, p = 0.23).
In summary, we have combined two high-resolution 
imaging techniques to reveal synapse loss in the frontal cor-
tex of ALS patients. We show that ALS patients with cogni-
tive impairment have lower synaptic densities than controls. 
Synapse density did not differ in the primary motor cortex 
between ALS and controls, most likely due to the signifi-
cant cortical thinning we observed in the ALS motor cortex. 
These findings significantly advance our understanding of 
ALS-associated neuropathology and identify the underly-
ing neurobiological substrate for cognitive decline in ALS. 
Further, these results suggest potential synaptic biomarkers 
for predicting which ALS patients will experience cogni-
tive changes, and point to the potential of synapse-directed 
therapeutics to combat both the cognitive and potentially 
also the motor symptoms of ALS.
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